Valuation: Novavax, Inc.

Market Cap 1.56B 1.33B 1.25B 1.14B 2.16B 148B 2.18B 14.75B 5.74B 74.89B 5.85B 5.72B 248B P/E 2026 *
-15.1x
P/E 2027 * -42.1x
Enterprise Value 1.78B 1.52B 1.43B 1.3B 2.46B 169B 2.48B 16.82B 6.55B 85.43B 6.67B 6.52B 283B EV / Sales 2026 *
4.76x
EV / Sales 2027 * 6.99x
Free-Float
93.05%
Yield 2026 *
-
Yield 2027 * -
1 day+6.55%
1 week+19.04%
Current month+28.96%
1 month+26.54%
3 months+2.50%
6 months-0.94%
Current year+40.48%
1 week 8.02
Extreme 8.02
9.58
1 month 7.15
Extreme 7.15
9.58
Current year 6.76
Extreme 6.76
11.97
1 year 6.2
Extreme 6.2
11.97
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
277.8
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 22/01/2023
Director of Finance/CFO 60 15/08/2021
Chief Tech/Sci/R&D Officer - 31/12/2021
Director TitleAgeSince
Director/Board Member 73 05/08/2010
Director/Board Member 66 31/10/2018
Director/Board Member 60 15/06/2020
Date Insider Type Main position Quantity % Market Cap.
20/06/26 Fiscal year

Director

37,760 0.0230%
18/06/26 Free

Director

35,450 0.0216%
01/03/26 Fiscal year

Chief Financial Officer

275,198 0.1694%
Change 5-day change 1-year change 3-year change Capi.($)
+6.55%+19.04%+25.53%+17.27% 1.56B
-0.45%+2.28%+2.46%+24.58% 51.65B
-0.09%-2.14%+492.60%+537.84% 45.31B
-0.32%+8.08%+37.97%+18.45% 42.7B
+1.18%+1.96%+21.95%+89.69% 42.79B
-2.27%-3.02%+14.22%+51.50% 32.87B
-0.96%+4.03%+31.55%+136.34% 17.14B
+0.41%+1.66% - - 16.61B
+0.03%+4.95%+13.15%+30.93% 15.01B
-0.31%+6.61%+81.37%+48.53% 14.21B
Average +0.39%+4.58%+80.09%+106.13% 27.98B
Weighted average by Cap. -0.23%+2.83%+104.12%+134.76%

Financials

2026 *2027 *
Net sales 373M 320M 299M 274M 516M 35.55B 521M 3.53B 1.38B 17.94B 1.4B 1.37B 59.41B 266M 228M 214M 195M 368M 25.38B 372M 2.52B 981M 12.8B 999M 978M 42.4B
Net income -108M -92.16M -86.35M -78.88M -149M -10.25B -150M -1.02B -397M -5.17B -404M -395M -17.13B -37.93M -32.5M -30.45M -27.82M -52.5M -3.62B -53.01M -359M -140M -1.82B -142M -139M -6.04B
Net Debt 219M 188M 176M 161M 303M 20.88B 306M 2.07B 807M 10.53B 822M 804M 34.88B 303M 260M 243M 222M 420M 28.91B 424M 2.87B 1.12B 14.58B 1.14B 1.11B 48.3B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
25/08/26 US$9.440 +6.55% 7,107,633
24/08/26 US$8.860 -0.89% 5,579,176
21/08/26 US$8.940 +6.18% 10,448,189
20/08/26 US$8.420 -4.21% 5,976,486
19/08/26 US$8.790 +10.84% 11,451,112
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
9.440USD
Average target price
14.00USD
Spread / Average Target
+48.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVAX Stock